A new risk model may help identify which patients with chronic kidney disease (CKD) and diabetes are more likely to develop hyperkalemia, granting physicians more confidence in prescribing medications ...

The FDA has granted Priority Review to finerenone (Kerendia) for adults with type 1 diabetes and CKD, following FINE-ONE trial data showing a 25% reduction in UACR.

Please provide your email address to receive an email when new articles are posted on . Patients with a urine albumin-creatinine ratio of at least 3,500 mg/g had high rates of hyperkalemia. High rates ...

Finerenone led to a 25% greater reduction in urinary albumin-to-creatinine ratio than placebo in adults with type 1 diabetes and chronic kidney disease. Hyperkalemia occurred in more ...

Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for KERENDIA ® (finerenone), which ...

Medically reviewed by Paria Sanaty Zadeh, PharmD Key Takeaways Serious side effects are more likely to occur when taking high ...

NEW YORK--(BUSINESS WIRE)--AccurKardia, an innovator in ECG-based diagnostics technology, has announced that it has received Breakthrough Device Designation by the U.S. Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . Lorundrostat was associated with a significant reduction in systolic BP for patients with CKD and uncontrolled ...

Kidney patients need to monitor potassium carefully, as even everyday foods can push levels dangerously high. Here are the ...